SERVIER
Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates.
Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3
“For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are continuously searching for new ways to give these patients more hope,” said Professor Eric Van Cutsem, Leuven, Belgium “The data from TASCO1 are very encouraging and provide evidence that trifluridine/tipiracil + bevacizumab is a beneficial treatment combination for these patients.”
In the exploratory phase II TASCO1 study, 153 patients were randomized and followed until September 1, 2020.1 The updated results showed that the median overall survival (OS) was 22.3 months with LONSURF + bevacizumab, whereas it was 17.6 months with C-B. This data translates into an improved median OS of 4.6 months with LONSURF + bevacizumab when compared with C-B (HR, 0.78; 95% CI, 0.55, 1.10). The survival probability at 18 months with LONSURF + bevacizumab was 0.62 (95% CI, 0.50, 0.72) and 0.47 (95% CI, 0.35, 0.57) with C-B.1 It should be noted that this was an exploratory, non-comparative study.
“We are very pleased with the updated results from the phase II TASCO1 study and we are continuing with our research into this promising combination in multiple mCRC settings. These data support all efforts that went into the confirmatory phase III SOLSTICE study. The results are expected in 2021,” said Patrick Therasse, M.D., Ph. D., Head of Servier Late Stage and Life Cycle Management Oncology, “Patients with mCRC who are not eligible for intensive chemotherapy have limited options and further clinical trials for additional treatments are highly anticipated by the clinical and patient communities alike.”
#ENDS#
About TASCO1
TASCO1 is an open-label, randomized, non-comparative Phase II study evaluating LONSURF® + bevacizumab and capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are non-eligible for intensive therapy. From April 2016 to March 2017, 153 patients were randomized and followed until end-of-study on September 1, 2020. The primary endpoint was progression-free survival, and the key secondary endpoint was overall survival.
For more information on TASCO1, please visit www.ClinicalTrials.gov (https://www.clinicaltrials.gov/ct2/show/NCT02743221 ). The ClinicalTrials.gov Identifier is NCT02743221.
About SOLSTICE
SOLSTICE is an open-label, randomized, multicentre Phase III trial in 854 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy. Patients were randomized 1:1 to receive first-line LONSURF® + bevacizumab versus capecitabine + bevacizumab. The primary objective is to demonstrate superior progression-free survival with LONSURF® + bevacizumab over capecitabine + bevacizumab. The first patient was enrolled in March 2019. Results are expected in 2021.
For more information on SOLSTICE, please visit www.ClinicalTrials.gov (https://www.clinicaltrials.gov/ct2/show/NCT03869892 ). The ClinicalTrials.gov Identifier is NCT03869892.
About Metastatic Colorectal Cancer (mCRC)
Colorectal cancer is the third most common cancer worldwide with approximately 1.8 million new diagnoses in 2018. Each year there are over 880,000 deaths, making it the second biggest cancer killer worldwide (after lung cancer).3
For those with metastatic disease (where the cancer has spread from the primary site), the average 5-year survival is approximately 11%.4 Standard chemotherapy regimens for advanced mCRC include fluoropyrimidines, oxaliplatin, irinotecan or targeted treatments, such as those that target vascular endothelial growth factors (VEGF) or endothelial growth factor receptors (EGFR).
Over the last decade, clinical outcomes for patients with mCRC have improved considerably due to the advent of novel treatment agents, predictive biomarkers, and a more strategic approach to the delivery of systemic therapies. Currently, the median overall survival for patients with mCRC being treated both in phase III trials and in large observational series or registries is 30 months – more than double that of 20 years ago.5,6,7
About LONSURF ®8
LONSURF® consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.
In the EU, LONSURF® is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti- VEGF agents, and anti-EGFR agents. LONSURF® is also indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer (mGC), including adenocarcinoma of the gastroesophageal junction (mGEJC), who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
As of November 2020, LONSURF® has been approved in 91 countries for the treatment of advanced mCRC and in 56 countries for the treatment of advanced mGC/mGEJC.
LONSURF® was discovered and developed by Taiho Pharmaceutical. In June 2015, Taiho Pharmaceutical and Servier entered into an exclusive license agreement for the co-development and commercialization of LONSURF® in Europe and other countries outside of the United States, Canada, Mexico, and Asia.
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information: www.servier.com
Follow us on Social Media:
1 Van Cutsem E, Danielewicz I, Saunders MP, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the final analysis on the overall survival. ASCO GI 2021.
2 Digestive Cancers Europe. Prevalence of Colorectal Cancer. https://digestivecancers.eu/colorectal-cancer/prevalence-of-colorectal-cancer-prevalence/?menu_id=13873 Last accessed December 2020.
3 World Health Organisation. GLOBOCAN. Cancer today. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages. https://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D Last accessed May 2020.
4 American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html Last accessed December 2020.
5 Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383(9927):1490-1502.
6 Price TJ, Segelov E, Burge M, et al. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther . 2014;14(12):1477-1493.
7 Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol . 2016;27(8):1386-1422.
8 European Medicines Agency. LONSURF European Public assessment report. https://www.ema.europa.eu/en/medicines/human/EPAR/LONSURF#authorisation-details-section Last accessed December 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210116005002/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alta Semper Secures USD 57.5 Million from EIB Group and IFC for Growth Fund II to Expand Healthcare Access Across Africa13.1.2026 19:30:00 CET | Press release
Alta Semper Capital LLP (“Alta Semper”), a London-based private equity firm focused on healthcare and consumer investments in high-growth markets, today announced that it has secured USD 57.5 million in commitments to Alta Semper Growth Fund II. These commitments come from a consortium of investors including the European Investment Bank (EIB) Group and the International Finance Corporation (IFC). This landmark partnership was signified earlier today with a momentous signing ceremony held at a Government Ministry in Cairo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113837616/en/ Andrew McDowell (EIB), Cheick Oumar Sylla (IFC), Gelsomina Vigliotti (EIB), Rania Al-Mashat (Minister of Planning, Economic Development and International Cooperation of Egypt), Bassel Rahmy (MSMEDA), Afsane Jetha (CEO, Alta Semper) and Mark Bryson-Richardson MBE (British Ambassador to Egypt) at the signing ceremony in Cairo. (Photo: AETOSWire)
500 Global and Creators HQ Support Creators and Founders Building Startups Collectively Valued at US$130M+13.1.2026 17:00:00 CET | Press release
500 Global, one of the world’s most active Silicon Valley-based venture capital firms1, and Creators HQ, the first content creator hub in the UAE and the Middle East enabling the creator ecosystem globally, announced the Creators Ventures Accelerator program is building and supporting creator-led startups collectively valued at over US$130 million.2 The Creators Ventures Accelerator received over 1,100 applications from content creators and technology startup founders across more than 70 countries. Following a competitive selection process, 21 creators and founders were chosen for the program. This cohort serves a community of 20M+ followers, subscribers, and users across platforms. “Creators represent a growing class of bona fide entrepreneurs, with 50 million creators globally, projected to grow at 10-20% annually over the next 5 years. The first iteration of this industry was built on visibility and virality to monetize. With consumers getting savvier and more discerning, we believe
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press release
The agreement builds on Nexo’s long-term approach to partnerships with established global sports institutions. Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title spons
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release
At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom